Core Viewpoint - The company has received the drug registration certificate for Arolol hydrochloride tablets (10mg) from the National Medical Products Administration, allowing for production approval [1] Group 1: Drug Approval - The drug Arolol hydrochloride is indicated for primary hypertension, angina pectoris, tachyarrhythmias, and essential tremor [1] - The company received the acceptance notice for the application on March 26, 2024, and has recently obtained the approval from the National Medical Products Administration [1] - The approval of the drug registration certificate is considered equivalent to passing the consistency evaluation according to national policies [1] Group 2: R&D Investment - The total R&D investment for the drug Arolol hydrochloride has reached RMB 3.9707 million (unaudited) as of the date of the announcement [1]

Core Points - Fuyuan Pharmaceutical (601089) experienced a significant decline of 9.66% in its stock price, with a trading volume of 7.29 billion yuan and a turnover rate of 6.18% [2] - The stock was listed on the Shanghai Stock Exchange for a daily price deviation of -10.90%, with a net sell-off of 42.23 million yuan from brokerage seats [2] - The company reported a revenue of 1.634 billion yuan for the first half of the year, reflecting a year-on-year decrease of 1.30%, and a net profit of 268 million yuan, down 7.83% year-on-year [2] Trading Data - The top five brokerage seats accounted for a total transaction of 206 million yuan, with a buying amount of 82.08 million yuan and a selling amount of 124 million yuan, resulting in a net sell-off of 42.23 million yuan [2] - The largest buying brokerage was Founder Securities Co., Ltd. with a purchase amount of 23.62 million yuan, while the largest selling brokerage was Dongfang Securities Co., Ltd. with a selling amount of 27.07 million yuan [2] Fund Flow - The stock saw a net outflow of 232 million yuan from major funds, with a significant outflow of 222 million yuan from large orders and a net outflow of 9.91 million yuan from medium orders [2] - Over the past five days, the net inflow of major funds was 76.64 million yuan [2]

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the drug registration certificate for Amlodipine Benazepril Capsules, which will enhance the company's product line and market competitiveness [1][4]. Drug Registration Certificate Details - The drug is approved for production by the National Medical Products Administration, with the registration certificate number 2025S02582 [1]. - Amlodipine Benazepril Capsules are indicated for patients whose blood pressure is not adequately controlled by either Amlodipine or Benazepril alone, or for those requiring a switch from separate Amlodipine and Benazepril tablets [1]. R&D Investment - The company has invested a total of RMB 8.1616 million (approximately 1.1 million USD) in the research and development of this drug [2]. Market Situation of Similar Drugs - According to data from Minai Network, the sales revenue of Amlodipine Benazepril oral formulations in China is approximately RMB 1.12 billion (about 160 million USD) for 2024 [3]. - The sales distribution includes RMB 727 million (about 102 million USD) from urban public hospitals and county-level public hospitals, RMB 167 million (about 24 million USD) from urban community centers and township health clinics, and RMB 226 million (about 32 million USD) from urban pharmacies and online pharmacies [3]. Impact on the Company - The approval of the drug will enrich the company's product line and enhance its market competitiveness [4].

Core Viewpoint - The innovative drug concept stocks experienced a decline, with several companies seeing significant drops in their stock prices [1] Group 1: Stock Performance - Shuyou Shen and Qianyan Biology both fell over 10% [1] - Fuyuan Pharmaceutical hit the daily limit down [1] - Baihua Pharmaceutical, Asia-Pacific Pharmaceutical, Wanbangde, Bailitianheng, and Ruizhiyiyuan all dropped over 5% [1]

Group 1 - The A-share market experienced fluctuations in the innovative drug sector, with significant declines in several stocks [1] - Fuyuan Pharmaceutical hit the daily limit down, while Frontier Biotech dropped over 10% [1] - Other companies such as Baihua Pharmaceutical, Jimin Health, Shutaishen, and Bailitianheng saw declines exceeding 5% [1]

Group 1 - The innovative drug concept sector experienced fluctuations in early trading, with several companies facing significant declines [1] - Fuyuan Pharmaceutical hit the daily limit down, indicating a strong negative market reaction [1] - Frontier Biotech dropped over 10%, reflecting investor concerns in the sector [1] Group 2 - Other companies such as Baihua Pharmaceutical, Jimin Health, Shutaishen, Bailitianheng, and Chengdu Xian Dao also saw declines exceeding 5% [1]

Core Viewpoint - Fuyuan Pharmaceutical has received approval from the National Medical Products Administration for the production of Amlodipine Benazepril Capsules, marking a significant milestone for the company in expanding its product offerings [1] Group 1 - The approved drug contains Amlodipine (5mg) and Benazepril (10mg) per capsule, indicating a combination therapy for hypertension [1] - The drug registration certificate number is 2025S02582, which formalizes the approval process [1]

Group 1 - Huida Sanitary Ware plans to publicly transfer 100% equity and debt of Guangxi Xingaosheng, with debt amounts of 132 million and 138 million yuan as of June 30, 2025 [1] - Sainuo Medical received administrative regulatory measures from Tianjin Securities Regulatory Bureau due to inaccurate information disclosure in quarterly reports [2][3] - Jiangling Motors reported August vehicle sales of 30,003 units, a year-on-year increase of 8.92% [6] Group 2 - Jimin Health's controlling shareholder plans to reduce its stake by up to 3%, totaling 15.75 million shares [7] - Satellite Chemical announced routine maintenance of polyethylene and ethylene glycol facilities, expected to last 45 days [8] - Hubei Yihua's 200,000-ton caustic soda project has been successfully put into production [10] Group 3 - Shanghai Pharmaceuticals' Dihydroxypropyl Theophylline Injection has passed the consistency evaluation for generic drugs [13] - Ningbo Construction's subsidiaries won construction projects worth 1.117 billion yuan [16] - Wens Foodstuff reported August sales revenue of 4.825 billion yuan from live pigs, with a year-on-year decrease in revenue and price [28] Group 4 - Long-term Logistics announced the resignation of its deputy general manager due to personal reasons [44] - Huaming Equipment proposed a cash dividend of 2 yuan per 10 shares, totaling 179 million yuan [46] - Transsion Holdings plans to distribute a cash dividend of 0.8 yuan per share [49]

Market Overview - The chemical pharmaceutical sector experienced a decline of 2.93% on September 4, with Nanjing New Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Haijing Pharmaceutical: closed at 21.20, up 9.67% with a trading volume of 55,600 shares [1] - Jiankai Technology: closed at 99.80, up 7.60% with a trading volume of 44,400 shares [1] - Fuyuan Pharmaceutical: closed at 27.13, up 6.98% with a trading volume of 384,900 shares [1] - Conversely, significant decliners included: - Nanjing New Pharmaceutical: closed at 13.27, down 10.82% with a trading volume of 240,800 shares [2] - Maiwei Biotech: closed at 54.22, down 9.59% with a trading volume of 278,800 shares [2] - Yipinhong: closed at 67.27, down 7.58% with a trading volume of 124,800 shares [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 2.173 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.619 billion yuan [2][3] - The capital flow for specific stocks indicated: - Fuyuan Pharmaceutical had a net inflow of 212 million yuan from institutional investors [3] - Chenshin Pharmaceutical experienced a net inflow of 117 million yuan from institutional investors [3] - Qianyan Biotech had a net inflow of 102 million yuan from institutional investors [3]

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the drug registration certificate for Amlodipine Besilate and Benazepril Hydrochloride Capsules, which will enhance the company's product line and market competitiveness [1][2]. Drug Registration Certificate Details - The drug is classified as a Class 3 chemical drug and is prescribed for patients whose blood pressure is not adequately controlled by Amlodipine or Benazepril alone [1]. - The drug's specifications include 5mg of Amlodipine Besilate and 10mg of Benazepril Hydrochloride per capsule [1]. - The registration certificate number is 2025S02582, and the drug is categorized as a prescription medication [1]. Market Information - The total sales of Amlodipine Besilate and Benazepril Hydrochloride Capsules in China for 2024 are estimated to be approximately 1.12 billion yuan, with sales in urban public hospitals and county-level public hospitals accounting for 727 million yuan [1]. - Sales from urban community centers and township health clinics are projected to be 167 million yuan, while urban pharmacies and online pharmacies are expected to generate 226 million yuan [1]. Company Impact - The approval of the drug registration certificate is expected to enrich the company's product portfolio and improve its market competitiveness [2].